Sutro Biopharma DEF 14A: Executive Equity Awards Detailed
Ticker: STRO · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1382101
| Field | Detail |
|---|---|
| Company | Sutro Biopharma, Inc. (STRO) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, proxy-statement
TL;DR
Sutro Biopharma DEF 14A out: Executive equity award values for 2022-2024 detailed.
AI Summary
Sutro Biopharma, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2022, 2023, and 2024. The filing includes information on the change in fair value of outstanding equity awards granted in prior years and year-end fair values for awards granted in covered years for both PEO and Non-PEO members.
Why It Matters
This filing provides transparency into how Sutro Biopharma compensates its top executives, offering insights into the value of equity awards and their potential impact on shareholder value.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present immediate financial risks.
Key Numbers
- 2024 — Fiscal Year (Reporting period for equity awards)
- 2023 — Fiscal Year (Reporting period for equity awards)
- 2022 — Fiscal Year (Reporting period for equity awards)
Key Players & Entities
- SUTRO BIOPHARMA, INC. (company) — Filer
- 0000950170-25-058774 (filing_id) — Accession Number
- 20250425 (date) — Filing Date
- 1231 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation and related matters.
What specific financial data related to equity awards is detailed in the filing?
The filing details the year-end fair value of equity awards granted in covered years and the change in fair value of outstanding equity awards granted in prior years for both PEO and Non-PEO members.
For which fiscal years are the equity award details provided?
The equity award details are provided for the fiscal years ending December 31, 2022, 2023, and 2024.
What is Sutro Biopharma's Standard Industrial Classification (SIC) code?
Sutro Biopharma's SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When was Sutro Biopharma, Inc. previously known by another name?
Sutro Biopharma, Inc. was formerly known as Sutro Biopharma Inc. and changed its name on November 27, 2006.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding SUTRO BIOPHARMA, INC. (STRO).